Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Bartmeyer

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Journal of the International AIDS Society|November 15, 2014
Characterization of natural polymorphic sites of the HIV-1 integrase before the introduction of HIV-1 integrase inhibitors in GermanyKarolin Meixenberger, Kaveh Pouran Yousef, Sybille Somogyi, et al.
Plos One|October 16, 2010
Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter CohortBarbara Bartmeyer, Claudia Kuecherer, Claudia Houareau, et al.
Journal of Virological Methods|June 3, 2018
Robust and sensitive subtype-generic HIV-1 pol genotyping for use with dried serum spots in epidemiological studiesAndrea Hauser, Karolin Meixenberger, Patrycja Machnowska, et al.
Journal of Virological Methods|February 23, 2020
Comparison of two immunoassays for concurrent detection of HCV antigen and antibodies among HIV/HCV co-infected patients in dried serum/plasma spotsAmare Eshetu, Andrea Hauser, Daniel Schmidt, et al.
Antiviral Therapy|August 23, 2012
Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infectionDaniela Zugna, Ronald B Geskus, Bianca De Stavola, et al.
Virology Journal|November 16, 2017
Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitorsKarolin Meixenberger, Kaveh Pouran Yousef, Maureen Rebecca Smith, et al.
Plos One|May 3, 2014
First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter studyFabia Zu Knyphausen, Ramona Scheufele, Claudia Kücherer, et al.
BMC Infectious Diseases|July 12, 2017
Surveillance of recent HIV infections among newly diagnosed HIV cases in Germany between 2008 and 2014Alexandra Hofmann, Andrea Hauser, Ruth Zimmermann, et al.
Infection|September 28, 2022
Low incidence of HIV infection and decreasing incidence of sexually transmitted infections among PrEP users in 2020 in GermanyDaniel Schmidt, Christian Kollan, Barbara Bartmeyer, et al.
Plos One|July 24, 2008
CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individualDjin-Ye Oh, Heiko Jessen, Claudia Kücherer, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Journal of the International AIDS Society|November 15, 2014
Characterization of natural polymorphic sites of the HIV-1 integrase before the introduction of HIV-1 integrase inhibitors in GermanyKarolin Meixenberger, Kaveh Pouran Yousef, Sybille Somogyi, et al.
Plos One|October 16, 2010
Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter CohortBarbara Bartmeyer, Claudia Kuecherer, Claudia Houareau, et al.
Journal of Virological Methods|June 3, 2018
Robust and sensitive subtype-generic HIV-1 pol genotyping for use with dried serum spots in epidemiological studiesAndrea Hauser, Karolin Meixenberger, Patrycja Machnowska, et al.
Journal of Virological Methods|February 23, 2020
Comparison of two immunoassays for concurrent detection of HCV antigen and antibodies among HIV/HCV co-infected patients in dried serum/plasma spotsAmare Eshetu, Andrea Hauser, Daniel Schmidt, et al.
Antiviral Therapy|August 23, 2012
Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infectionDaniela Zugna, Ronald B Geskus, Bianca De Stavola, et al.
Virology Journal|November 16, 2017
Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitorsKarolin Meixenberger, Kaveh Pouran Yousef, Maureen Rebecca Smith, et al.
Plos One|May 3, 2014
First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter studyFabia Zu Knyphausen, Ramona Scheufele, Claudia Kücherer, et al.
BMC Infectious Diseases|July 12, 2017
Surveillance of recent HIV infections among newly diagnosed HIV cases in Germany between 2008 and 2014Alexandra Hofmann, Andrea Hauser, Ruth Zimmermann, et al.
Infection|September 28, 2022
Low incidence of HIV infection and decreasing incidence of sexually transmitted infections among PrEP users in 2020 in GermanyDaniel Schmidt, Christian Kollan, Barbara Bartmeyer, et al.
Plos One|July 24, 2008
CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individualDjin-Ye Oh, Heiko Jessen, Claudia Kücherer, et al.
Pageof 4